HOME >> BIOLOGY >> NEWS
Second generation targeted antibodies - It's all in the binding

The overproduction, or 'overexpression', of the epidermal growth factor receptor (EGFR) is one of the most common aberrations in cancer, and subsequently agents that inhibit EGFR are among the most hotly-pursued potential products in the pharmaceutical industry. Now, just weeks after one of the first anti-EGFR antibodies, ImClone's Erbitux (Cetuximab), was approved for use in Europe and the USA, a 'second generation' anti-EGFR antibody is set to enter early-phase clinical trials in Australia. In two articles recently published in the Journal of Biological Chemistry, research teams from the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have elucidated the unique binding properties of an anti-EGFR antibody, called 806, that is able to discriminate between EGFR molecules on cancer cells and EGFR molecules on normal cells.

"There is already one anti-EGFR antibody on the market, and there are several more in clinical trials," says Dr. Andrew Scott, the Head of the LICR Melbourne Branch's Clinical Program. "Although these anti-EGFR antibodies do show some anti-tumor activity in patients, they are far from ideal because they bind to EGFR on both cancer cells and normal cells. As a result, they target normal tissues as well as the tumor, and side-effects, although mild, are common." Perhaps more importantly, the 'first generation' antibodies are limited in their clinical application and their capacity for improvement. "We need to increase the therapeutic efficacy of the available anti-EGFR antibodies," explains Dr. Scott. "What we would like to do is attach a lethal agent to an anti-EGFR antibody, such as a cytotoxic molecule or a radioisotope, so that the agent is targeted directly to the cancer cell. With the 806 antibody, we should be able to both interfere with EGFR signaling and deliver lethal agents to cancers, without causing severe side-effects through the destruction of normal, healthy cells, particularly in the liver an
'"/>

Contact: Sarah L. White, Ph.D.
swhite@licr.org
212-450-1543
Ludwig Institute for Cancer Research
6-May-2004


Page: 1 2 3

Related biology news :

1. Second call for proposals for the European Young Investigator Award
2. Secondary complications and restoration of function in SCI
3. Second EMBO International Practical Workshop for Science Teachers
4. NTP-CERHR announces the Second Phthalates Expert Panel Meeting to be held December 15-17, 1999
5. In Logged Forests, Hunting of Wildlife Becomes Deadly Second Harvest
6. Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life
7. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
8. When One Gene Has Two Roles, Its Second Function May Be Missed
9. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
10. The Second Visible Human Project Conference
11. Researchers Take A Second Look At Homocysteines Link To Heart Disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Second generation targeted antibodies all the binding

(Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/24/2015)... report analyzes the worldwide markets for Face and Voice Biometrics in ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Middle East ... Latin America . Annual estimates and forecasts are provided for ... provided for these markets. Market data and analytics are derived from ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. (“Immunovaccine” ... of a fraudulent press release disseminated this morning by ... from Immunovaccine. This press release states that Immunovaccine has ... The press release did not originate from Immunovaccine ... within the press release. Please note that all ...
(Date:2/27/2015)... and SUMMERLAND, British Columbia ... (NYSE: XON ), a leader in synthetic ... to acquire  Okanagan Specialty Fruits (OSF), the pioneering ... , the world,s first non-browning apple. Through the acquisition, ... fruit that is more appetizing and convenient for consumers ...
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... announced that longer-term toxicology studies for its newly ... arthritis, or RA, have been completed. The results ... the U.S. Food and Drug Administration. The feedback ... completion of the ongoing first-in-human study. Additional preclinical ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Immunovaccine Disclaims Hoax Press Release 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
Cached News: